Skip to main content
. Author manuscript; available in PMC: 2016 Sep 7.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Jun 12;82(2):e119–e127. doi: 10.1016/j.ijrobp.2011.04.058

Table 1. Patient and tumor characteristics of 15 head-and-neck cancer patients.

Age (y)* 15, 57.0, 55.8 ± 7.5 (45.0–68.0)
Smoking (pack-years) 15, 36.0, 47.4 ± 29.0 (10.0–100.0)
Treatment elapsed (d) 15, 47.0, 50.4 ± 7.0 (42.0–66.0)
GTV-tumor – primary (cm3) 14, 15.7, 39.5 ± 44.4 (2.9–162.5)
GTV-tumor – nodal (cm3) 10, 21.0, 47.0 ± 58.7 (2.4–179.8)
GTV-tumor – max (cm3) 15, 39.5, 60.1 ± 55.2 (8.8–179.8)
Sex
 Male 12 (80.0)
 Female 3 (20.0)
Race
 White 8 (53.3)
 Black 5 (33.3)
 Other 2 (13.3)
T stage
 T0 1 (6.7)
 T1 1 (6.7)
 T2 6 (40.0)
 T3 3 (20.0)
 T4 4 (26.7)
Nodal stage
 N0 5 (33.3)
 N1 1 (6.7)
 N2 8 (53.3)
 N3 1 (6.7)
M stage
 M0 14 (93.3)
 M1 1 (6.7)
AJCC stage
 I 0
 II 2 (13.3)
 III 3 (20.0)
 IV 10 (66.7)
Total dose (Gy)/fractions
 69.96/33 13 (86.7)
 70.00/35 1 (6.7)
 72.00/42 1 (6.7)
Primary site
 Nasopharynx 2 (13.3)
 Oropharynx/oral 6 (40.0)
 Hypopharynx/larynx 5 (33.3)
 Other 2 (13.3)

Abbreviations: AJCC = American Joint Committee on Cancer; GTV = gross tumor volume; max = maximum of primary or nodal GTV.

*

Data in first six rows presented as n, median, mean ± SD (range). Other data presented as n (%).